StockIQ.techVaxcyte, Inc. (PCVX) Stock Analysis
Free AI-powered analysis and research for Vaxcyte, Inc. stock
Sector: Healthcare
PCVX snapshot
Data as of 9 Oct 2026 close. Updated daily.
Vaxcyte, Inc. scores 68/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 62% of its 52-week range, up 63.3% over the past year. Latest reported figures show a profit margin of 0.0% and return on equity of -36.5%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Weak Profit Margin (0.0%): -8
- Low Debt (0.04 D/E): +8
- Strong Liquidity (5.72 Current Ratio): +8
- Negative ROE (-36.5%): -10
- Strong Long-term Uptrend: +8
- Overextended (+63.3% over 1 year): -8
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full PCVX report
Vaxcyte, Inc. (PCVX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze PCVX Now →📰 Latest Update
Vaxcyte stock falls on $1B dual offering launch
Mon, October 5, 2026 at 9:26 PM UTC 2 min read
Vaxcyte (PCVX) shares declined following the announcement of a $1 billion dual offering, which includes both common stock and convertible senior notes. This move is aimed at raising capital to support the company's ongoing development and commercialization efforts. Investors may be concerned about potential dilution of their shares and the implications of increased debt, impacting the stock's performance in the near term.